

## Practical management of non-muscle invasive bladder cancer (NMIBC)

ESU Course 37

**Monday, 27 March**  
**08:30 - 11:30**

**Location:** Room 12, Capital suite (level 3)

**Chair:** J.A. Witjes, Nijmegen (NL)

### **Aims and objectives of this session**

This course was updated significantly in 2016 (more cases, other subjects and more interaction) which was evaluated in a very positive way by the participants. Therefore, we chose to keep the course unchanged in 2017.

After discussing diagnostic opportunities of NMIBC, we will spent considerable time on the technique of TUR, including tips, potential problems, en bloc resection, TUR in difficult situations and TUR with enhanced imaging. We will illustrate this with video's and discuss pitfalls with the audience.

Additional risk adapted intravesical treatment including new modalities, including limitations of these recommendations, will be discussed next.

After that, we will discuss daily problems with regard to complications during and after intravesical therapy and how to prevent and treat that.

Finally a topic that remains a clinical problem remains on the program: how to deal with abnormal cytology including locations outside the bladder.

Since we try to keep the course as practical in interactive as possible, with case discussions, videos, feedback and time for Q&A, we might not cover all topics as we experienced in 2016 in Munich. However, the lively discussions and interaction was highly appreciated.

In the end we hope that attendees will have updated their guideline knowledge, but also know what (not) to do in exceptional or complicated cases, and what alternatives could be.

08:30 - 11:30

### **Introduction**

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

### **Diagnosis, markers and innovations**

J. Palou, Barcelona (ES)

08:30 - 11:30

### **TUR technique: Tips and tricks, problems and bloc resection, TUR at difficult places, Re-TUR: Enhanced imaging (including many video's)**

M. Babjuk, Prague (CZ)

08:30 - 11:30

### **Risk groups and guideline treatment: What is clearly established**

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

### **Comments on guideline treatment including BCG shortage and new treatment modalities**

M. Babjuk, Prague (CZ)

08:30 - 11:30

### **Complications of intravesical therapy**

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

### **How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations**

J. Palou, Barcelona (ES)